mesalamine has been researched along with Urticaria in 3 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Urticaria: A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mesalazine was administered to 33 patients with CIU, starting at 500 mg/day with weekly incremental dosing to a total of 1 g/day." | 1.38 | Mesalazine as a new therapeutic option for chronic idiopathic urticaria. ( Abdollahee, A; Dastgheib, L; Jowkar, F; Namazi, MR, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dastgheib, L | 1 |
| Jowkar, F | 1 |
| Abdollahee, A | 1 |
| Namazi, MR | 1 |
| Vázquez Fuertes, L | 1 |
| Martínez-Cócera, C | 1 |
| Robledo Echarren, T | 1 |
| Domínguez Ortega, J | 1 |
| González Gutiérrez, ML | 1 |
| Varela, S | 1 |
| Díez, MS | 1 |
| Gonzalez, C | 1 |
| Gonzalez de la Cuesta, C | 1 |
| Arenas, L | 1 |
| Feijoó, R | 1 |
| Menéndez, M | 1 |
3 other studies available for mesalamine and Urticaria
| Article | Year |
|---|---|
Mesalazine as a new therapeutic option for chronic idiopathic urticaria.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Female; Humans; Male; Mesalamine; P | 2012 |
[Induction of tolerance in hypersensitivity to mesalazine (5-ASA)].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Desensitization, Immunologic; Drug Hypersensitivity; | 2005 |
Oral desensitization to 5-ASA.
Topics: Administration, Oral; Anaphylaxis; Angioedema; Desensitization, Immunologic; Drug Hypersensitivity; | 2002 |